Title

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO I hereby revoke all previous powers of attorney given in the application identified in the attached statement under

	y appoint:						
	y appoint.					٦	
	- I seminate a decodated with the Costonier Number.			95671			
OR							
Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):							
Г		Name	Registration	_	Name		
. L			Number		Name		Registration Number
· L							
Г				_			
				-			
- 1							
L	01/(4) 41 41 41						
as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents							
attached	to this form in a	ccordance with 37 CFR 3.73(b).	med decording to		saigninent records	or assignment o	ocuments
Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:							
				io unauriou dia	concent under 57 (2FTC 3.73(b) to.	
The address associated with Customer Number: 95671							
OR	The address as	ssociated with Customer Number:		00071			l
	rm or						
Individual Name							
Address							
City			State			Zip	
Country						ip	
Telepho	ne			Email			
Assignee	Name and Addi	ress:					
Synopsys, Inc.							
700 E. Middlefield Rd.							
Mountain View, CA 94043							
A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be							
A copy o	or this form, to each applicati	ogether with a statement und	er 37 CFR 3.73	3(b) (Form P1	O/SB/96 or eq	uivalent) is req	uired to be
filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee.							
and must identify the application in which this Power of Attorney is to be filed.							
SIGNATURE of Assignee of Record The individual whose signature and title is supplied below is authorized to act on behalf of the assignee							
Signature	-	~ 8 Min			Date <	1/2/1/2	
Name	 	Julie Stephenson			Telephor	1120/10	14040
	1 \	, Julie Stephen	JUI I		j relephor	ne 650.584	1.1249 I

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and Inst collection of immination is required by 37 CPR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the LISPT) to princess) an application. Confidentiality is appointed by 35 LIS C 222 and 37 CPR 1.11 and 1.11. This colorion is estimated to the 33 minutes to complete, including pathological properties, and submitting the completed application form to the LISPTO. Time will vary depending upon the individual case. Any LISPTO control of the complete depolation form to the LISPTO. Time will vary depending upon the individual case. Any LISPTO control of the Complete of the Complete depolation for reducing this bushing, should be sent to the Chief information Officer. LISPTO control of the Complete of the Chief Individual Case. Any LISPTO complete of the Chief Individual Case. Any LISPTO commissioner of Commerce, P.O. Star 460, Alexandria, VA 2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patents, P.O. Star 460, Alexandria, VA 2231-1450.

Associate General Counsel, Chief IP Counsel

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information socicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patient and Trademark Office is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested information, the U.S. Patient and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (6 U.S. 652a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is recurred by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing coursel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, by whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued nation.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.